Publications by authors named "M Ocker"

Claim this Profile
T
Targeted therapy for biliary tract cancer: facts and fictions as well as demands and challenges.
Daniel Neureiter, Peter Ellinghaus, Matthias Ocker

Expert Rev Anticancer Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New frontiers in the pharmacological management of biliary tract carcinomas: the emerging role of drug conjugates.
Matthias Ocker, Christian Mayr, Petra Huber-Cantonati, Tobias Kiesslich, Daniel Neureiter

Expert Opin Pharmacother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The importance of preclinical models for cholangiocarcinoma drug discovery.
Felix J Krendl, Florian Primavesi, Rupert Oberhuber, Daniel Neureiter, Matthias Ocker

Expert Opin Drug Discov· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.
Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Matthias Ocker

Nat Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells.
Dino Bekric, Tobias Kiesslich, Matthias Ocker, Martina Winklmayr, Markus Ritter

PLoS One· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis